Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

Community clinic-based lifestyle change for prevention of metabolic syndrome: Rationale, design and methods of the 'Vida Sana/healthy life' program.

Risica PM, McCarthy M, Barry K, Oliverio SP, De Groot AS.

Contemp Clin Trials Commun. 2018 Oct 25;12:123-128. doi: 10.1016/j.conctc.2018.10.002. eCollection 2018 Dec.

2.

Bridging the [Health Equity] Gap at a Free Clinic for Uninsured Residents of Rhode Island.

Hindocha P, Nair NJ, Pigoga JL, Barry K, McCarthy M, Almeida-Monroe V, De Groot AS.

R I Med J (2013). 2018 Nov 1;101(9):27-31.

PMID:
30384516
3.

T cell epitope engineering: an avian H7N9 influenza vaccine strategy for pandemic preparedness and response.

Moise L, M Biron B, Boyle CM, Kurt Yilmaz N, Jang H, Schiffer C, M Ross T, Martin WD, De Groot AS.

Hum Vaccin Immunother. 2018;14(9):2203-2207. doi: 10.1080/21645515.2018.1495303. Epub 2018 Sep 5.

4.

Mass spectrometry-assisted identification of ADAMTS13-derived peptides presented on HLA-DR and HLA-DQ.

Hrdinová J, Verbij FC, Kaijen PHP, Hartholt RB, van Alphen F, Lardy N, Ten Brinke A, Vanhoorelbeke K, Hindocha PJ, De Groot AS, Meijer AB, Voorberg J, Peyron I.

Haematologica. 2018 Jun;103(6):1083-1092. doi: 10.3324/haematol.2017.179119. Epub 2018 Mar 22.

5.

T-cell epitope content comparison (EpiCC) of swine H1 influenza A virus hemagglutinin.

Gutiérrez AH, Rapp-Gabrielson VJ, Terry FE, Loving CL, Moise L, Martin WD, De Groot AS.

Influenza Other Respir Viruses. 2017 Nov;11(6):531-542. doi: 10.1111/irv.12513.

6.

An immunoinformatics-derived DNA vaccine encoding human class II T cell epitopes of Ebola virus, Sudan virus, and Venezuelan equine encephalitis virus is immunogenic in HLA transgenic mice.

Bounds CE, Terry FE, Moise L, Hannaman D, Martin WD, De Groot AS, Suschak JJ, Dupuy LC, Schmaljohn CS.

Hum Vaccin Immunother. 2017 Dec 2;13(12):2824-2836. doi: 10.1080/21645515.2017.1329788. Epub 2017 Jun 2.

7.

Prevalence of HPV 16 and 18 and attitudes toward HPV vaccination trials in patients with cervical cancer in Mali.

Téguété I, Dolo A, Sangare K, Sissoko A, Rochas M, Beseme S, Tounkara K, Yekta S, De Groot AS, Koita OA.

PLoS One. 2017 Feb 23;12(2):e0172661. doi: 10.1371/journal.pone.0172661. eCollection 2017.

8.

Knowledge, attitudes, practices and willingness to vaccinate in preparation for the introduction of HPV vaccines in Bamako, Mali.

De Groot AS, Tounkara K, Rochas M, Beseme S, Yekta S, Diallo FS, Tracy JK, Teguete I, Koita OA.

PLoS One. 2017 Feb 13;12(2):e0171631. doi: 10.1371/journal.pone.0171631. eCollection 2017.

9.

De-immunized and Functional Therapeutic (DeFT) versions of a long lasting recombinant alpha interferon for antiviral therapy.

Mufarrege EF, Giorgetti S, Etcheverrigaray M, Terry F, Martin W, De Groot AS.

Clin Immunol. 2017 Mar;176:31-41. doi: 10.1016/j.clim.2017.01.003. Epub 2017 Jan 10.

PMID:
28089609
10.

Innovation, urgency and acceptance at the 9th Vaccine Renaissance.

De Groot AS, Moise L.

Hum Vaccin Immunother. 2016 Dec;12(12):3186-3188. doi: 10.1080/21645515.2016.1254853. No abstract available.

11.

In Vivo Validation of Predicted and Conserved T Cell Epitopes in a Swine Influenza Model.

Gutiérrez AH, Loving C, Moise L, Terry FE, Brockmeier SL, Hughes HR, Martin WD, De Groot AS.

PLoS One. 2016 Jul 13;11(7):e0159237. doi: 10.1371/journal.pone.0159237. eCollection 2016.

12.

Agility in adversity: Vaccines on Demand.

De Groot AS, Moise L, Olive D, Einck L, Martin W.

Expert Rev Vaccines. 2016 Sep;15(9):1087-91. doi: 10.1080/14760584.2016.1205951. Epub 2016 Jul 18. Review.

PMID:
27389971
13.

Barriers to Health Insurance Pre- and Post-Affordable Care Act Implementation in Providence, RI.

Pigoga J, Kibria F, Pinilla M, Bicki A, Joseph V, De Groot AS.

R I Med J (2013). 2015 Dec 1;98(12):35-9.

PMID:
26623454
14.

T cell epitope redundancy: cross-conservation of the TCR face between pathogens and self and its implications for vaccines and autoimmunity.

Moise L, Beseme S, Tassone R, Liu R, Kibria F, Terry F, Martin W, De Groot AS.

Expert Rev Vaccines. 2016 May;15(5):607-17. doi: 10.1586/14760584.2016.1123098. Epub 2016 Feb 15. Review.

PMID:
26588466
15.

Hit-and-run, hit-and-stay, and commensal bacteria present different peptide content when viewed from the perspective of the T cell.

He L, De Groot AS, Bailey-Kellogg C.

Vaccine. 2015 Nov 27;33(48):6922-9. doi: 10.1016/j.vaccine.2015.08.099. Epub 2015 Oct 1.

PMID:
26428457
16.

Development and validation of an epitope prediction tool for swine (PigMatrix) based on the pocket profile method.

Gutiérrez AH, Martin WD, Bailey-Kellogg C, Terry F, Moise L, De Groot AS.

BMC Bioinformatics. 2015 Sep 15;16:290. doi: 10.1186/s12859-015-0724-8.

17.

8th vaccine renaissance: A creative nexus for vaccine developers.

Johnson H, Moise L, Menge A, Beseme S, De Groot AS.

Hum Vaccin Immunother. 2015;11(9):2294-5. doi: 10.1080/21645515.2015.1069453. Epub 2015 Jul 9. No abstract available.

18.

iVAX: An integrated toolkit for the selection and optimization of antigens and the design of epitope-driven vaccines.

Moise L, Gutierrez A, Kibria F, Martin R, Tassone R, Liu R, Terry F, Martin B, De Groot AS.

Hum Vaccin Immunother. 2015;11(9):2312-21. doi: 10.1080/21645515.2015.1061159.

19.

An immunoinformatic approach for identification of Trypanosoma cruzi HLA-A2-restricted CD8(+) T cell epitopes.

Eickhoff CS, Van Aartsen D, Terry FE, Meymandi SK, Traina MM, Hernandez S, Martin WD, Moise L, De Groot AS, Hoft DF.

Hum Vaccin Immunother. 2015;11(9):2322-8. doi: 10.1080/21645515.2015.1061160. Epub 2015 Jun 24.

20.

H7N9 T-cell epitopes that mimic human sequences are less immunogenic and may induce Treg-mediated tolerance.

Liu R, Moise L, Tassone R, Gutierrez AH, Terry FE, Sangare K, Ardito MT, Martin WD, De Groot AS.

Hum Vaccin Immunother. 2015;11(9):2241-52. doi: 10.1080/21645515.2015.1052197. Epub 2015 Jun 19.

21.

Preclinical development of HIvax: Human survivin highly immunogenic vaccines.

Hoffmann PR, Panigada M, Soprana E, Terry F, Bandar IS, Napolitano A, Rose AH, Hoffmann FW, Ndhlovu LC, Belcaid M, Moise L, De Groot AS, Carbone M, Gaudino G, Matsui T, Siccardi A, Bertino P.

Hum Vaccin Immunother. 2015;11(7):1585-95. doi: 10.1080/21645515.2015.1050572.

22.

Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma.

Tomimaru Y, Mishra S, Safran H, Charpentier KP, Martin W, De Groot AS, Gregory SH, Wands JR.

Vaccine. 2015 Mar 3;33(10):1256-66. doi: 10.1016/j.vaccine.2015.01.037. Epub 2015 Jan 25.

23.

Partial pathogen protection by tick-bite sensitization and epitope recognition in peptide-immunized HLA DR3 transgenic mice.

Shattuck WM, Dyer MC, Desrosiers J, Fast LD, Terry FE, Martin WD, Moise L, De Groot AS, Mather TN.

Hum Vaccin Immunother. 2014;10(10):3048-59. doi: 10.4161/21645515.2014.985498.

24.

Immune camouflage: relevance to vaccines and human immunology.

De Groot AS, Moise L, Liu R, Gutierrez AH, Tassone R, Bailey-Kellogg C, Martin W.

Hum Vaccin Immunother. 2014;10(12):3570-5. doi: 10.4161/hv.36134.

25.

VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.

Leblanc P, Moise L, Luza C, Chantaralawan K, Lezeau L, Yuan J, Field M, Richer D, Boyle C, Martin WD, Fishman JB, Berg EA, Baker D, Zeigler B, Mais DE, Taylor W, Coleman R, Warren HS, Gelfand JA, De Groot AS, Brauns T, Poznansky MC.

Hum Vaccin Immunother. 2014;10(10):3022-38. doi: 10.4161/hv.34413. Review.

26.

Tregitope: Immunomodulation powerhouse.

Cousens L, Najafian N, Martin WD, De Groot AS.

Hum Immunol. 2014 Dec;75(12):1139-46. doi: 10.1016/j.humimm.2014.10.012. Epub 2014 Oct 22.

27.

Identification and retrospective validation of T-cell epitopes in the hepatitis C virus genotype 4 proteome: an accelerated approach toward epitope-driven vaccine development.

Abdel-Hady KM, Gutierrez AH, Terry F, Desrosiers J, De Groot AS, Azzazy HM.

Hum Vaccin Immunother. 2014;10(8):2366-77. doi: 10.4161/hv.29177.

28.

C3d adjuvant effects are mediated through the activation of C3d-specific autoreactive T cells.

De Groot AS, Ross TM, Levitz L, Messitt TJ, Tassone R, Boyle CM, Vincelli AJ, Moise L, Martin W, Knopf PM.

Immunol Cell Biol. 2015 Feb;93(2):189-97. doi: 10.1038/icb.2014.89. Epub 2014 Nov 11.

29.

Smarter vaccine design will circumvent regulatory T cell-mediated evasion in chronic HIV and HCV infection.

Moise L, Terry F, Gutierrez AH, Tassone R, Losikoff P, Gregory SH, Bailey-Kellogg C, Martin WD, De Groot AS.

Front Microbiol. 2014 Oct 6;5:502. doi: 10.3389/fmicb.2014.00502. eCollection 2014.

30.

Time for T? Immunoinformatics addresses vaccine design for neglected tropical and emerging infectious diseases.

Terry FE, Moise L, Martin RF, Torres M, Pilotte N, Williams SA, De Groot AS.

Expert Rev Vaccines. 2015 Jan;14(1):21-35. doi: 10.1586/14760584.2015.955478. Epub 2014 Sep 5. Review.

31.

HCV epitope, homologous to multiple human protein sequences, induces a regulatory T cell response in infected patients.

Losikoff PT, Mishra S, Terry F, Gutierrez A, Ardito MT, Fast L, Nevola M, Martin WD, Bailey-Kellogg C, De Groot AS, Gregory SH.

J Hepatol. 2015 Jan;62(1):48-55. doi: 10.1016/j.jhep.2014.08.026. Epub 2014 Aug 23.

PMID:
25157982
32.

Dendritic cell-mediated, DNA-based vaccination against hepatitis C induces the multi-epitope-specific response of humanized, HLA transgenic mice.

Mishra S, Lavelle BJ, Desrosiers J, Ardito MT, Terry F, Martin WD, De Groot AS, Gregory SH.

PLoS One. 2014 Aug 11;9(8):e104606. doi: 10.1371/journal.pone.0104606. eCollection 2014.

33.

Integrated assessment of predicted MHC binding and cross-conservation with self reveals patterns of viral camouflage.

He L, De Groot AS, Gutierrez AH, Martin WD, Moise L, Bailey-Kellogg C.

BMC Bioinformatics. 2014;15 Suppl 4:S1. doi: 10.1186/1471-2105-15-S4-S1. Epub 2014 Mar 19.

34.

ICoVax 2013: the 3rd ISV Pre-conference Computational Vaccinology Workshop.

De Groot AS, De Groot P, He Y.

BMC Bioinformatics. 2014;15 Suppl 4:I1. doi: 10.1186/1471-2105-15-S4-I1. Epub 2014 Mar 19.

35.

Vida Sana: a lifestyle intervention for uninsured, predominantly Spanish-speaking immigrants improves metabolic syndrome indicators.

Buckley J, Yekta S, Joseph V, Johnson H, Oliverio S, De Groot AS.

J Community Health. 2015 Feb;40(1):116-23. doi: 10.1007/s10900-014-9905-z.

PMID:
24984599
36.

CHOPPI: a web tool for the analysis of immunogenicity risk from host cell proteins in CHO-based protein production.

Bailey-Kellogg C, Gutiérrez AH, Moise L, Terry F, Martin WD, De Groot AS.

Biotechnol Bioeng. 2014 Nov;111(11):2170-82. doi: 10.1002/bit.25286. Epub 2014 Jul 14.

37.

HPV knowledge and vaccine acceptance in an uninsured Hispanic population in Providence, RI.

Chau J, Kibria F, Landi M, Reilly M, Medeiros T, Johnson H, Yekta S, De Groot AS.

R I Med J (2013). 2014 May 1;97(5):35-9.

PMID:
24791266
38.

Human immune responses to H. pylori HLA Class II epitopes identified by immunoinformatic methods.

Zhang S, Desrosiers J, Aponte-Pieras JR, DaSilva K, Fast LD, Terry F, Martin WD, De Groot AS, Moise L, Moss SF.

PLoS One. 2014 Apr 16;9(4):e94974. doi: 10.1371/journal.pone.0094974. eCollection 2014.

39.

Peptide-pulsed dendritic cells induce the hepatitis C viral epitope-specific responses of naïve human T cells.

Mishra S, Losikoff PT, Self AA, Terry F, Ardito MT, Tassone R, Martin WD, De Groot AS, Gregory SH.

Vaccine. 2014 May 30;32(26):3285-92. doi: 10.1016/j.vaccine.2014.03.083. Epub 2014 Apr 8.

PMID:
24721533
40.

Assessment of hypertension guidelines adherence at a free clinic serving a predominantly Latino population in Providence, RI.

Kibria F, Peters JL, Shulman C, Joseph V, De Groot AS.

R I Med J (2013). 2014 Mar 3;97(3):43-7.

PMID:
24596931
41.

Cross-conservation of T-cell epitopes: now even more relevant to (H7N9) influenza vaccine design.

De Groot AS, Moise L, Liu R, Gutierrez AH, Terry F, Koita OA, Ross TM, Martin W.

Hum Vaccin Immunother. 2014;10(2):256-62. doi: 10.4161/hv.28135. Epub 2014 Feb 13. Review.

42.

Tregitope peptides: the active pharmaceutical ingredient of IVIG?

De Groot AS, Cousens L, Mingozzi F, Martin W.

Clin Dev Immunol. 2013;2013:493138. doi: 10.1155/2013/493138. Epub 2013 Dec 25. Review.

43.

T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation.

Jawa V, Cousens LP, Awwad M, Wakshull E, Kropshofer H, De Groot AS.

Clin Immunol. 2013 Dec;149(3):534-55. doi: 10.1016/j.clim.2013.09.006. Epub 2013 Sep 25. Review.

44.

Do Tregitopes have the potential to impact the current treatment landscape of autoimmune diseases?

De Groot AS.

Expert Rev Clin Immunol. 2013 Dec;9(12):1155-7. doi: 10.1586/1744666X.2013.858602. No abstract available.

PMID:
24215404
45.

Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics.

De Groot AS, Terry F, Cousens L, Martin W.

Expert Rev Clin Pharmacol. 2013 Nov;6(6):651-62. doi: 10.1586/17512433.2013.835698. Review.

46.

Immunization with cross-conserved H1N1 influenza CD4+ T-cell epitopes lowers viral burden in HLA DR3 transgenic mice.

Moise L, Tassone R, Latimer H, Terry F, Levitz L, Haran JP, Ross TM, Boyle CM, Martin WD, De Groot AS.

Hum Vaccin Immunother. 2013 Oct;9(10):2060-8. doi: 10.4161/hv.26511. Epub 2013 Sep 17.

47.

Elevated antigen-specific Th2 type response is associated with the poor prognosis of hand, foot and mouth disease.

Wei R, Xu L, Zhang N, Zhu K, Yang J, Yang C, Deng C, Zhu Z, De Groot AS, Altmeyer R, Zeng M, Leng Q.

Virus Res. 2013 Oct;177(1):62-5. doi: 10.1016/j.virusres.2013.07.009. Epub 2013 Jul 22.

PMID:
23886670
48.

Making vaccines "on demand": a potential solution for emerging pathogens and biodefense?

De Groot AS, Einck L, Moise L, Chambers M, Ballantyne J, Malone RW, Ardito M, Martin W.

Hum Vaccin Immunother. 2013 Sep;9(9):1877-84. doi: 10.4161/hv.25611. Epub 2013 Jul 22. Review.

49.

Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes.

Hui DJ, Basner-Tschakarjan E, Chen Y, Davidson RJ, Buchlis G, Yazicioglu M, Pien GC, Finn JD, Haurigot V, Tai A, Scott DW, Cousens LP, Zhou S, De Groot AS, Mingozzi F.

Mol Ther. 2013 Sep;21(9):1727-37. doi: 10.1038/mt.2013.166. Epub 2013 Jul 16.

50.

Universal H1N1 influenza vaccine development: identification of consensus class II hemagglutinin and neuraminidase epitopes derived from strains circulating between 1980 and 2011.

Moise L, Terry F, Ardito M, Tassone R, Latimer H, Boyle C, Martin WD, De Groot AS.

Hum Vaccin Immunother. 2013 Jul;9(7):1598-607. doi: 10.4161/hv.25598. Epub 2013 Jul 11.

PMID:
23846304

Supplemental Content

Loading ...
Support Center